Rigel Pharmaceuticals (RIGL) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Verastem (VSTM) over the past year, losing 13.3% versus a loss of 36.7%. Over five years, RIGL leads with a +44.7% price change compared with -80.3% for VSTM. Verastem is the larger company by market cap ($797.7 million vs $754.9 million), about 1.1 times the size.
Rigel Pharmaceuticals converts more of its revenue into profit, with a net margin of 124.7% versus -677.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RIGL | VSTM |
|---|---|---|
| Share price | $40.09 | $6.33 |
| Market cap | $754.89M | $797.67M |
| 1-day change | -2.67% | -7.73% |
| YTD return | -6.40% | -18.01% |
| 1-year return | -13.26% | -36.70% |
| 5-year return | +44.73% | -80.32% |
| P/E ratio (TTM) | 2.49 | — |
| Forward P/E | 8.39 | — |
| EPS (TTM) | $16.07 | $-1.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $294.28M | $30.91M |
| Revenue growth (YoY) | +64.15% | +209.14% |
| Net income (latest FY) | $367.02M | $-209.47M |
| Gross margin | 93.33% | — |
| Operating margin | 42.63% | -550.33% |
| Net margin | 124.72% | -677.59% |
| 52-week high | $52.61 | $10.82 |
| 52-week low | $24.95 | $3.43 |
| Distance from 52-week high | -23.80% | -41.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +60.64% | +172.04% |
| Average volume | 248.06K | 3.53M |
| Shares outstanding | 18.83M | 126.01M |
| Employees | 172 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed VSTM by 23.4 percentage points over the past year.
- Rigel Pharmaceuticals is more profitable, keeping 124.7 cents of every revenue dollar as net income versus -677.6 cents for Verastem.
- Verastem grew revenue faster in its latest fiscal year (+209.14% vs +64.15%).
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
RIGL vs VSTM FAQ
Which is bigger, Rigel Pharmaceuticals or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $797.67M compared with $754.89M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, RIGL or VSTM?
RIGL returned -13.26% over the past 12 months, compared with -36.70% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Rigel Pharmaceuticals and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.